Pharmanovia A/S — Credit Rating and Financial Key Figures
CVR number: 32287824
Ørestads Boulevard 108, 2300 København S
Income statement (kDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | 3 730.18 | 15 223.66 | 3 431.17 | 5 883.90 | 4 683.83 |
| Employee benefit expenses | -13 352.49 | -15 840.27 | -15 916.52 | -2 421.01 | -1 606.57 |
| Total depreciation | -2 131.03 | -1 182.68 | -7 650.99 | - 116.69 | - 151.95 |
| EBIT | -1 573.00 | - 241.00 | -2 707.00 | 3 346.20 | 2 925.31 |
| Other financial income | 0.00 | 115.76 | 1 108.84 | ||
| Other financial expenses | -1 961.97 | - 228.85 | -1 464.05 | - 178.71 | -1 351.37 |
| Pre-tax profit | -13 715.32 | -2 028.14 | -21 600.38 | 3 283.24 | 2 682.79 |
| Income taxes | 11 879.32 | 1 756.14 | 18 696.38 | 224.95 | - 436.16 |
| Net earnings | -1 836.00 | - 272.00 | -2 904.00 | 3 508.19 | 2 246.63 |
Assets (kDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Development expenditure | 5 579.82 | 9 558.64 | 4 837.49 | 398.02 | 338.81 |
| Intangible rights | 269.44 | 185.05 | |||
| Intangible assets total | 5 579.82 | 9 558.64 | 4 837.49 | 667.46 | 523.87 |
| Machinery and equipment | 883.01 | 566.06 | 171.29 | 54.19 | 49.63 |
| Tangible assets total | 883.01 | 566.06 | 171.29 | 54.19 | 49.63 |
| Other receivables | -25 254.49 | -24 160.36 | -65 863.42 | ||
| Investments total | -25 254.49 | -24 160.36 | -65 863.42 | ||
| Long term receivables total | |||||
| Semifinished products | 660.94 | 16.78 | 0.51 | 9.94 | 21.96 |
| Raw materials and consumables | 2 203.91 | 3 240.18 | 3 001.73 | 404.32 | 325.13 |
| Finished products/goods | 4 724.46 | 4 551.98 | 18 187.36 | 3 357.09 | 6 586.39 |
| Inventories total | 7 589.32 | 7 808.94 | 21 189.60 | 3 771.34 | 6 933.48 |
| Current trade debtors | 8 562.43 | 6 868.70 | 31 620.04 | 5 649.46 | 16 419.43 |
| Current amounts owed by group member comp. | 1 452.68 | 1 133.62 | 737.13 | 6 835.82 | 20 839.67 |
| Prepayments and accrued income | 1 452.35 | 1 508.65 | 1 972.40 | 163.70 | |
| Current other receivables | 45.18 | 46.13 | 810.92 | 940.55 | |
| Short term receivables total | 11 512.64 | 9 557.10 | 35 140.49 | 12 648.99 | 38 199.65 |
| Cash and bank deposits | 3 594.71 | 421.61 | 14 755.56 | 1 217.31 | 2 020.89 |
| Cash and cash equivalents | 3 594.71 | 421.61 | 14 755.56 | 1 217.31 | 2 020.89 |
| Balance sheet total (assets) | 3 905.00 | 3 752.00 | 10 231.00 | 18 359.29 | 47 727.52 |
Equity and liabilities (kDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Share capital | 1 000.00 | 1 000.00 | 1 000.00 | 134.26 | 134.26 |
| Other reserves | -14 842.83 | -13 078.69 | 5 618.69 | ||
| Retained earnings | 17 973.83 | 14 381.69 | -4 586.70 | -1 005.67 | 2 502.53 |
| Profit of the financial year | -1 836.00 | - 272.00 | -2 904.00 | 3 508.19 | 2 246.63 |
| Shareholders equity total | 2 295.00 | 2 031.00 | - 872.00 | 2 636.78 | 4 883.41 |
| Provisions | 14 842.83 | 13 078.69 | -5 618.69 | ||
| Non-current owed to group member | 2 347.17 | 3 251.26 | 60 707.65 | 5 147.33 | |
| Non-current liabilities total | 2 347.17 | 3 251.26 | 60 707.65 | 5 147.33 | |
| Current loans from credit institutions | 2.84 | 16.71 | |||
| Current trade creditors | 3 089.87 | 3 276.49 | 1 728.09 | 470.45 | 1 295.61 |
| Current owed to group member | 4 457.20 | 2 345.46 | 2 245.93 | 8 950.09 | 34 381.62 |
| Short-term deferred tax liabilities | 146.66 | 260.36 | |||
| Other non-interest bearing current liabilities | 2 127.42 | 3 929.45 | 17 903.45 | 1 005.14 | 6 889.80 |
| Current liabilities total | 9 674.50 | 9 551.41 | 21 877.46 | 10 575.18 | 42 844.11 |
| Balance sheet total (liabilities) | 29 159.49 | 27 912.36 | 76 094.42 | 18 359.29 | 47 727.52 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.